From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer

From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer

Bibliographic Details
Main Authors:	Robert Pirker, Martin Filipits
Format:	Article
Language:	English
Published:	Elsevier 2019-09-01
Series:	ESMO Open
Online Access:	https://esmoopen.bmj.com/content/4/5/e000548.full

Similar Items

Clinical Efficacy of Crizotinib in Advanced ALK Positive  Non-small Cell Lung Cancer
by: Jing ZHAO, et al.
Published: (2015-10-01)

Efficacy and Safety of Crizotinib in Advanced or Recurrent  ALK-positive Non-small Cell Lung Cancer
by: Xiaoyan LI, et al.
Published: (2019-08-01)

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
by: Jiacong Wei, et al.
Published: (2018-01-01)

Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC
by: Ryo Toyozawa, MD, et al.
Published: (2020-06-01)

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
by: Chan-Young Ock, et al.
Published: (2019-09-01)

Use of crizotinib for refractory ALK-positive lymphomas
by: L N Shelikhova, et al.
Published: (2017-07-01)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
by: Hayato Mizuta, et al.
Published: (2021-02-01)

Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer
by: Okuma Y, et al.
Published: (2015-06-01)

Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report
by: Go Makimoto, et al.
Published: (2021-03-01)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
by: Giroux Leprieur E, et al.
Published: (2016-06-01)

Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis
by: Hao Tang, et al.
Published: (2021-06-01)

Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis
by: Takashi Kobayashi, et al.
Published: (2021-08-01)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
by: Rui-Lian Chen, et al.
Published: (2018-11-01)

Treatment of Patients with ALK Gene Rearranged Non-small Cell Lung Cancer  after Resistance to Crizotinib
by: Tao JIANG, et al.
Published: (2015-02-01)

Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
by: Tung Hoang, et al.
Published: (2020-02-01)

Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.
by: Yabing Cao, et al.
Published: (2014-01-01)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
by: T. Lee Collier PhD, et al.
Published: (2017-10-01)

Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
by: Vikas T. Talreja, et al.
Published: (2020-01-01)

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients
by: Jacques Cadranel, et al.
Published: (2018-02-01)

Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.
by: Shun Lu, et al.
Published: (2018-01-01)

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
by: Jain RK, et al.
Published: (2017-10-01)

Cost-Utility Analysis of Crizotinib as First Line Medication on Late Stage ALK Positive Non-Small Cell Lung Cancer Patients in Taiwan
by: Kang-Yi Liu, et al.
Published: (2016)

Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer
by: Xiao-Hong Xie, et al.
Published: (2021-03-01)

Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis
by: Koichi Ando, et al.
Published: (2021-07-01)

lincROR influences the stemness and crizotinib resistance in EML–ALK+ non-small-cell lung cancer cells
by: Yang Y, et al.
Published: (2018-06-01)

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
by: Peng Song, et al.
Published: (2019-04-01)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
by: Yen-Ting Lin, et al.
Published: (2019-09-01)

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study
by: Sergey V. Orlov, et al.
Published: (2021-08-01)

ALK and IGF-1R as independent targets in crizotinib resistant lung cancer
by: Christabel Wilson, et al.
Published: (2017-10-01)

Fatal Haemoptysis Associated with Dramatic Response to Crizotinib in an ALK-Rearranged Lung Adenocarcinoma
by: Elodie Mussat, et al.
Published: (2016-03-01)

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.
by: Marine Sivignon, et al.
Published: (2020-01-01)

Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib
by: Mizuki Nishino, et al.
Published: (2020-01-01)

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
by: Katayama, Ryohei, et al.
Published: (2011)

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program
by: Nikolaj Frost, et al.
Published: (2021-02-01)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
by: Cao Q, et al.
Published: (2019-02-01)

ALK-driven tumors and targeted therapy: focus on crizotinib
by: Murga-Zamalloa C, et al.
Published: (2014-03-01)

Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib
by: Chun-wei Xu, et al.
Published: (2018-04-01)

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
by: Herbert H. Loong, et al.
Published: (2020-11-01)

EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER
by: A. A. Paichadze, et al.
Published: (2020-03-01)

Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
by: Tomoyo Taketa, et al.
Published: (2021-04-01)